Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 119 (1) , 55-57
- https://doi.org/10.1007/bf01209489
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activityInternational Journal of Gynecologic Cancer, 1992
- A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.Journal of Clinical Oncology, 1991
- A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.Journal of Clinical Oncology, 1990
- Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinomaGynecologic Oncology, 1987
- PHASE-I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CISPLATIN AND ETOPOSIDE1987
- Ovarian cancerCurrent Problems in Cancer, 1987
- Cisplatin Plus VP16 213 in Refractory Ovarian CarcinomaAmerican Journal of Clinical Oncology, 1987
- Etoposide (VP‐16) plus cisplatin (DDP): A new active chemotherapeutic combination in patients with stage iii‐iv ovarian adenocarcinomaJournal of Surgical Oncology, 1986
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIAActa Pathologica Microbiologica Scandinavica Section A Pathology, 1973